Harbor
AI system-of-record for clinical trial data
Note: This is a preliminary assessment based on limited publicly available information. We did not have access to LinkedIn profiles or live product screenshots for this analysis. We will update this entry with a more thorough review soon.
Verdict
Harbor is a strong setup: a domain expert who lived the pain (Albert's 4 years at Biolinq, including FDA authorization experience) paired with a technical founder who's shipped at scale (Google, Ramp, YC). The product is already live in real regulated studies, and the 10x configuration speed improvement on a 1600-subject trial is a compelling proof point. The market is large, B2B, and deeply underserved by aging incumbents. The main risks are long enterprise sales cycles in heavily regulated healthcare, the challenge of displacing entrenched EDC vendors with compliance-conservative pharma and medtech customers, and the gap between 'first few studies' and meaningful ARR. If they can convert that large trial into a reference customer and navigate GCP/21 CFR Part 11 validation requirements at scale, this could be a genuinely important company.
Active Founders
Albert is the co-founder and CEO of Harbor. Before Harbor, Albert helped run clinical trials and regulatory strategy at Biolinq, helping take the company's first and flagship product from prototype through its first human studies and eventual FDA De Novo authorization. Prior to Biolinq, Albert led diabetes technology coverage at Close Concerns, a boutique consulting firm. Albert studied biomedical engineering at the University of Michigan.
Nate is the co-founder and CTO of Harbor. He spent the last five years working at tech companies ranging from seed-stage startups to Ramp and Google. He’s built zero-to-one systems as the first employee of another YC startup and wrote smart contracts securing millions in assets at a blockchain infrastructure company. He studied pure math at UCLA and computer science at the University of Michigan.